Paclitaxel micelle formulation - Nippon Kayaku/NanoCarrier
Alternative Names: Macromolecular micelle paclitaxel; NK 105; Polymeric micelle paclitaxelLatest Information Update: 26 Apr 2022
At a glance
- Originator NanoCarrier
- Developer Nippon Kayaku
- Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Breast cancer
- Phase II Gastric cancer
- No development reported Solid tumours
Most Recent Events
- 26 Apr 2022 Paclitaxel micelle formulation is still in phase II trials for Breast cancer (Recurrent, Late-stage disease) in Japan (IV) (JapicCTI-183868)
- 12 Nov 2021 Nippon Kayaku completes a phase II clinical trial in Breast cancer (Recurrent, Late-stage disease) in Japan (IV) (JapicCTI-183868)
- 09 Oct 2019 Nippon Kayaku completes enrolment in a phase II clinical trials in Breast cancer (Recurrent, Late-stage disease) in Japan before October 2019 (IV) (JapicCTI-183868)